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Abstract
Background: Poor gene transfer efficiency has been a major problem in developing an effective gene therapy for 
cystic fibrosis (CF) airway disease. Lysophosphatidylcholine (LPC), a natural airway surfactant, can enhance viral gene 
transfer in animal models. We examined the electrophysiological and physical effect of airway pre-treatment with 
variants of LPC on lentiviral (LV) vector gene transfer efficiency in murine nasal airways in vivo.
Methods: Gene transfer was assessed after 1 week following nasal instillations of a VSV-G pseudotype LV vector pre-
treated with a low and high dose of LPC variants. The electrophysiological effects of a range of LPC variants were 
assessed by nasal transepithelial potential difference measurements (TPD) to determine tight junction permeability. 
Any physical changes to the epithelium from administration of the LPC variants were noted by histological methods in 
airway tissue harvested after 1 hour.
Results: Gene transduction was significantly greater compared to control (PBS) for our standard LPC (palmitoyl/
stearoyl mixture) treatment and for the majority of the other LPC variants with longer acyl chain lengths. The LPC 
variant heptadecanoyl also produced significantly greater LV gene transfer compared to our standard LPC mixture. LV 
gene transfer and the transepithelial depolarization produced by the 0.1% LPC variants at 1 hour were strongly 
correlated (r2 = 0.94), but at the 1% concentration the correlation was less strong (r2 = 0.59). LPC variants that displayed 
minor to moderate levels of disruption to the airway epithelium were clearly associated with higher LV gene transfer.
Conclusions: These findings show the LPC variants effect on airway barrier function and their correlation to the 
effectiveness of gene expression. The enhanced expression produced by a number of LPC variants should provide new 
options for preclinical development of efficient airway gene transfer techniques.
Introduction
The search for a safe and effective gene therapy for cystic
fibrosis (CF) airway disease has been underway for more
than 15 years, and throughout this time three issues have
underscored the slow progress in this field: the poor effi-
ciency of gene transfer; the short persistence of gene
expression; and the abrogation of initial gene expression
by host inflammatory and immune responses [1,2].
Poor efficiency can be seen as a problem in general for
gene transfer to airways - evolution has produced a
extremely effective series of protective barriers and that
e f fi ci e n t l y  b l oc k,  r e m o v e  o r  d e s t r o y  t h e  b u l k  o f  v ect o r
doses delivered into the airway [3,4]. For a genetic disease
like CF, highly-persistent gene correction or complemen-
tation is necessary to counter the life-long effects of the
disease; in this regard lentivirus vectors are an obvious
choice because of their longevity of expression and
depending on their pseudotype, their ability to transduce
many cell types. Inflammatory and immune responses
have limited the therapeutic effectiveness of many other
viral vectors such as adenovirus and adeno-associated
adenovirus [5-7]. However, helper-dependent adenovirus
have shown enhanced efficiency and surprisingly high
levels of expression in mouse [8], rabbit and baboon lungs
[9,10] when delivered in conjunction with lysophosphati-
dylcholine (LPC). Nevertheless, the long term persistence
of expression from these vectors has not been adequately
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assessed. We have also demonstrated that high level long-
lasting lentiviral gene expression can be produced in
intact nasal airways of normal and CF mice after LPC
pre-treatment [11,12].
The major action of LPC in all these circumstance
appears to be the improvement of vector access to appro-
priate airway cell surface receptors as well as transient
disturbance of epithelial surface barrier function to per-
mit vector particle access to basolateral receptors and to
deeper-lying basal cells that may have progenitor-like
qualities. Following the success of our pre-treatment
studies using a standard and readily available natural
form of LPC (derived from egg yolk, a mixture of palmi-
toyl/stearoyl forms), we report here on studies designed
to determine whether molecular variants of LPC could
produce more effective enhancement of LV gene transfer
and/or reduce the potential for damage to the airway epi-
thelium.
Materials and methods
Nasal Dosing
Studies were conducted with approval from the Animal
Ethics Committee at the Women's and Children's Hospi-
tal, Adelaide, SA. Female C57Bl/6 mice, 8-10 weeks of age
were anaesthetised with 10 μl/g body weight of Domitor
(0.1 mg/ml, Orion Corporation, Finland) and Ketamine
(7.6 mg/ml, Parnell Laboratories Aust Pty Ltd) mixture,
delivered i.p. Anaesthesia was reversed with 2 μl/g i.p.
injection of atipamazole (0.5 mg/ml, Orion Corporation,
Finland).
LPC variants were obtained from Sigma-Aldrich
Chemical Co: L4129 egg yolk (the standard LPC molecule
used previously), L3135 decanoyl, L5629 lauroyl, L6629
myristoyl, L5254 palmitoyl, L5257 heptadecanoyl, L2131
stearoyl, and L1881 oleoyl. LPC variants differed only in
the length of their acyl chain (Table 1). PBS was used as a
vehicle-control and in preparation of both the 0.1% and
1% concentrations.
Gene Transfer
Instillations were made into the right nostril via  a
micropipettor with a gel-loading tip (Finnpipette), as
described previously [11,13]. Pre-treatment with LPC
variant or control (PBS) was via a 4 μl aliquot one hour
prior to a 20 μl bolus of the lentivirus (L VLacZ) vector
(self-inactivating HIV-1, VSV-G pseudotype under tran-
scriptional control of the simian virus 40 early promoter),
at a titre of 4 × 107 tu/ml, the latter delivered in 2 × 10 μl
aliquots over a minute, via  passive (inhalation-driven)
fluid uptake [11].
Assessment of gene expression
Mice were sacrificed 7 days post-treatment to quantify
gene transfer. Heads were processed to reveal LacZ gene
expression  via  the standard X-gal method previously
described [11,12]. The numbers and percentages of posi-
tive LacZ cells were counted in respiratory and transi-
tional epithelium in three standard head cross sections,
detailed in [12]. Sections were stained with haematoxylin
and eosin (H&E) to reveal cellular identity and morphol-
ogy, or safranin-O to provide a high contrast counterstain
for assessment of β-galactosidase gene expression (as
blue-stained cells, Fig 1a.).
Electrophysiological and Histological Actions of LPC
Epithelial Potential Difference
For assessment of tight junction permeability, the electro-
physiological integrity of mouse nasal airways was mea-
sured using the transepithelial potential difference (TPD)
measurement as previously described [11]. Briefly, fine
polyethylene tubing was inserted ~2.5 - 3 mm into the
right (dosed) nostril of the anaesthetized mouse, and the
TPD was recorded using DataStudio (Version 1.9.8r2,
Pasco Scientific, USA) until a steady plateau of at least 1
min was obtained. The ΔPD was calculated by subtract-
ing the TPD value recorded under basal conditions (per-
fusion with Krebs-buffered Ringers) from the value
recorded using low-chloride conditions (Krebs with NaCl
replaced with Na gluconate). The low chloride setting
was used to provide a large TPD value upon which any
changes induced by LPC could be more readily detected.
A large span of TPD value permits the readout variability
to be a smaller proportion of the signal, decreasing the
experimental-animal samples sizes required. Once base-
line ΔPD was established a 4 μl bolus of either PBS or
LPC variant was instilled into the same nostril and the
change in low chloride TPD measurement was continu-
ously recorded for a further hour. This provided an effect
time-course and a final value for the LPC-induced change
that would be present in our gene transfer studies, since
the subsequent gene vector deliveries were performed 1
hour after LPC treatment.
Table 1: Structural formula of the LPC variants, defined by 
the lengths of their acyl chains.
LPC Acyl Chain Structure M. W.
Decanoyl C10:0 C18H38NO7P 412
Lauroyl C12:0 C20H42NO7P 439
Myristoyl C14:0 C22H46NO7P 468
Palmitoyl C16:0 C24H50NO7P 496
Heptadecanoyl C17:0 C25H52NO7P 510
Palmitoyl:Stearoyl C16:C18 66%:33% 505
Stearoyl C18:0 C26H54NO7P 524
Oleoyl C18:1 C26H52NO7P 522Cmielewski et al. Respiratory Research 2010, 11:84
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Figure 1 LV gene transfer in nasal respiratory epithelium. (a) Histological examples of LV transduced (blue staining) cell types after 1 week. Left 
panel shows transduced ciliated and basal cells (solid arrow) and unciliated cells (open arrow, right panel). Safranin O staining, scale bar = 10 μm. LV 
Gene transfer at 1 week following 0.1% (b) and 1% (c) LPC variant pre-treatment. *p < 0.05 ANOVA against PBS, **p < 0.05 t-test C17:0 vs standard LPC 
(C16:C18), (n = 6/group). The proportion of respiratory cells types transduced following 0.1% (d) and 1% (e) LPC variant pre-treatment. Note: PBS is the 
same group of control animals in b-e) for Figure 1; a, b) for Figures 3, 5 and 7; and a-d) for Figure 4.Cmielewski et al. Respiratory Research 2010, 11:84
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Histology
Two weeks after the initial treatment the same LPC treat-
ment for that mouse was repeated into the right nostril.
Animals were sacrificed via CO2  asphyxiation after 1
hour, the usual time of our gene vector administration.
Heads were processed for histological examination to
produce standard cross sections (noted above, and see
[12]) and stained with H&E or Alcian Blue/Periodic Acid
Schiff reagent, to identify effects on epithelial morphol-
ogy and goblet cell mucin presence respectively. Goblet
cell numbers were counted in the first two standard cross
sections (equivalent to levels 6 and 16 in Mery et al [14],
in which the nasal septum separates both nostrils) in both
the left and right nostrils in all animals. The percentage of
goblet cells in the treated vs untreated side was then cal-
culated. A rank scale based on the level of epithelial dis-
turbance in the treated nostril was used to compare to the
disturbance in the untreated nostril. Both treated and
untreated regions could be examined in the same sec-
tions. The scale used was: 0 = no difference, 1 = Loss of
goblet mucin, 2 = loss of some cilia, 3 = physical disrup-
tion of cell-cell junctions, 4 = areas of exfoliation in the
epithelial layer.
Statistics
All data are expressed as the mean ± standard error of the
mean, and statistical analysis was performed using Sig-
maStat 3.01 (SPSS, Chicago, IL). Multiple treatment
groups were analyzed by one-way analysis of variance
(ANOVA) using post-test multiple comparison tech-
niques with statistical significance set at p = 0.05, and
power = 0.8. Student t-tests were performed to compare 2
groups, and standard transformations or appropriate
nonparametric methods were utilized where data did not
satisfy normality assumptions.
Results
LV Gene Expression
We first examined the effect of pre-treatment of a range
of LPC variants at a low (0.1% w/v) and high (1% w/v)
concentration on LV mediated gene transfer measured 1
week later (Fig. 1). The biologically occurring LPC mole-
cules palmitoyl-C16:0, stearoyl-C18:0 and oleoyl-C18:1
are phospholipids found in the fatty acids of many mam-
malian tissues [15-17]. Decanoyl-C10:0, lauroyl-C12:0
and myristoyl-C14:0 are LPC variants with short acyl
chains and heptadecanoyl-C17:0 has an un-even acyl
chain length that is not found in nature. We tested these
LPC variants against a PBS control as well as our standard
LPC (egg yolk derived LPC, a mixture of palmitoyl and
stearoyl (C16:C18) forms).
Gene transduction was significantly greater compared
to control (pre-treatment with PBS) at the low concentra-
tion for our standard LPC and 3 of the new LPC variants,
palmitoyl-C16:0, heptadecanoyl-C17:0 and stearoyl-
C18:0 (Fig. 1b, p < 0.05, ANOVA). The LPC variant hep-
tadecanoyl-C17:0 also produced significantly greater LV
gene transfer compared to our standard LPC mixture (p <
0.05, t-test). However, for the high dose tested (1%) all
LPC variants, except decanoyl-C10:0, produced LV gene
transfer greater than control (p < 0.05, ANOVA) and were
equivalent to our standard palmitoyl/stearoyl LPC mix-
ture (Fig. 1c).
Ciliated, basal and unciliated cells were the only respi-
ratory cell types transduced (Fig. 1 a, d-e). The propor-
tion of these three cell types differed with the different
concentration of LPC but not with the variants of LPC
pre-treatment. For 0.1% LPC concentration the majority
of cells transduced were ciliated (60%), 26% were uncili-
ated and basal cells compromised approximately 14%
(Fig. 1d). At the higher concentration of 1% LPC ciliated
cells were still the majority transduced (72%) however the
proportion of basal cells was 21% with unciliated cells at
7% (Fig. 1e). No olfactory, goblet or squamous epithelial
cells were transduced.
Electrophysiological Action of LPC
From the above experiments we selected four LPC vari-
ants that displayed key differences in LV gene transduc-
tion responses at both concentrations for further study.
Pre-treatment with decanoyl-C10:0 displayed no gene
transfer, stearoyl-C18:0 and heptadecanoyl-C17:0 had
similar or greater gene expression than our standard LPC,
and the fourth variant oleoyl-C18:1 produced an interme-
diate response, at the two concentrations tested. These
LPC variants, our standard LPC mixture, and a PBS con-
trol were examined for their effect on epithelial mem-
brane physiology. The assessment of epithelium electrical
potential difference (a measure of electrophysiological
integrity in part based on tight junction permeability)
was  via  the nasal transepithelial potential difference
(TPD) measurement. Under low-chloride perfusion (see
methods) a 4 μl aliquot of a particular LPC variant was
instilled and the TPD recorded continuously for a further
1 hour; four examples are shown in Fig. 2.
The PBS control (Fig. 2a) and the LPC variants that
resulted in no or little gene transfer (i.e. decanoyl-C10:0
(Fig. 2b) and 0.1% oleoyl-C18:1) produced a brief depo-
larization in the TPD level when the 4 μ1 bolus was
instilled but had returned to pre-instillation (baseline)
levels by the 1 hour time point. The LPC variants that
produced strong LV gene transfer showed either a grad-
ual (Fig. 2c) or an immediate depolarization towards zero
that persisted for the entire 1 hour post-instillation
period (Fig. 2d). All LPC variants that displayed a signifi-
cant difference in mouse nasal ΔPD at the 1 hour timeCmielewski et al. Respiratory Research 2010, 11:84
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point compared to the baseline ΔPD (Fig. 3a &3b, p <
0.05, ANOVA) corresponded to those mice displaying
more efficient LV gene transfer at 1 week.
More specifically, at 1 hour post-instillation, i.e. at the
usual time of gene vector instillation, the higher depolar-
izations in low-chloride TPD were correlated with higher
LV gene expression. LV gene transfer and the TPD depo-
l a r i z a t i o n  p r o d u c e d  b y  t h e  0 . 1 %  L P C  v a r i a n t s  w e r e
strongly correlated (r2 = 0.94 Pearson's correlation, p =
0.001, Fig 4a, c), but at the 1% LPC concentration the cor-
relation was less strong (r2 = 0.59, p = 0.077, Fig. 4b, d).
Epithelial Disturbance of LPC
Two weeks after TPD measurement (a time sufficient for
full regeneration of epithelium damaged by these proce-
dures [18]), the same LPC variant type and dose delivered
to that mouse was again instilled into the right nostril.
One hour later mice were sacrificed for histological prep-
aration of the nasal airways and assessed (compared to
the untreated nostril epithelium [19]) for changes in gob-
let cell number and mucin presence. In the untreated
nostril an average of 260 goblet cells were counted per
mouse. Any physical changes to the integrity of the epi-
thelial layer on the treated side were also noted. There
was a significant reduction in the number of mucin-con-
taining goblet cells of the epithelial layer in response to
nasal instillation after all LPC variants except for
decanoyl-C10:0 and when the PBS control treatment was
employed (Fig. 5a-b, p < 0.05, ANOVA, Holm-Sidak).
As a surfactant with detergent properties, LPC given at
high concentrations has the potential to produce physical
disturbance of the epithelium. We ranked the effects of
Figure 2 Representative traces of nasal potential difference measurements. Examples of TPD traces, monitored for up to 60 mins after addition 
of (a) PBS, (b) 0.1% LPC-decanoyl, (c) 0.1% LPC-standard and (d) 0.1% LPC-heptadecanoyl. B = basal Krebs, LC = low-chloride Krebs, LPC= addition of 
4 μl bolus of LPC into same nostril, PBS= addition of 4 μl bolus of PBS into same nostril. Traces are each representative of n = 5-6 mice.Cmielewski et al. Respiratory Research 2010, 11:84
http://respiratory-research.com/content/11/1/84
Page 6 of 11
LPC on the epithelium ranging from no effect; through to
mild perturbations, loss of cilia, and physical disruption
of cell-cell junctions; to areas of epithelial cell shrinkage
and/or exfoliation of the epithelial layer (Fig. 6). PBS con-
trol treatments as well as those LPC variants ineffective at
sustaining a TPD reduction (decanoyl-C10:0, 0.1% oleoyl-
C18:1) produced no physical disruption of the epithelial
layer in the treated side compared to the untreated side.
However, the LPC variants that displayed minor-moder-
ate levels of disruption to this layer (ranging from loss of
cilia to disruption of cell-cell membranes) were clearly
associated with higher LV gene transfer (Fig 7a, p < 0.05,
ANOVA). Indeed, even the LPC variants that produced
areas of cellular exfoliation (Fig. 7b, p < 0.05, ANOVA)
could nevertheless enhance LV gene transfer, albeit at a
lower efficacy.
In all studies procedures were well tolerated, post pro-
cedure weight changes were unremarkable and there was
no related morbidity and mortality.
Discussion
Despite the strong interest in gene therapy as a cure or
treatment for the chronic and progressive disease that
overtakes the cystic fibrosis lung, no clinically therapeu-
tic benefits have yet appeared due largely to ineffective
vector transduction [20] and host immune and inflam-
matory responses [5,6]. If the traditionally poor efficiency
of gene transfer can be improved there is the potential to
produce substantial and positive gene expression out-
c o m e s .  I n c r e a s i n g  t h e  e f f i c i e n c y  o f  g e n e  t r a n s d u c t i o n
would permit a reduction of the dose of vector and its
contaminants that should automatically help to reduce
the intensity of the immune and inflammatory responses.
The use of an enhancer such as LPC provides an effective
method to reduce the vector dose necessary to achieve a
given level of gene expression in vivo.
The efficiency of gene transfer with any vector can be
improved by increasing the ability of vector particles to
reach and remain near their target cells [21]. In normal
circumstances the availability of the majority of vector
particles delivered to the airways for transduction process
are rapidly and substantially reduced by the natural barri-
ers to airway infection. These include the mucus layer, the
mucociliary clearance that transports particles out of the
airway [22,23] and the glycocalyx [24] that can bind vec-
tor particles that escape these initial barriers and all can
prevent vector contact with the relevant cell-membrane
receptors. In terms of vectors that can also target basolat-
eral receptors, such as VSV-G pseudotyped LV vectors,
the tight junctions between the cells provide an addi-
tional barrier to transduction that must be considered.
Although airway gene transfer using a simian LV vector
pseudotyped with a Sendai virus envelope [25] or a feline
LV vector pseudotyped with a baculovirus GP64 envelope
[26] can effectively target the apical receptors in murine
nasal airway, a large dose (volume and titre) of the vector
and long residence time was needed to overcome these
initial barriers. The combination of LPC pretreatment
with the VSV-G pseudotyped LV vector permits trans-
duction at apical as well as basolateral sites, providing
immediate (apical) and potentially long term transduc-
tion via basally located progenitor cells [27].
Figure 3 Summary of change in potential difference after LPC administration. ΔPD monitored for 60 mins post (a) 0.1% and (b) 1% LPC variant 
instillation. B designates baseline ΔPD. Arrow designates instillation of LPC variant (or PBS); *p < 0.05, ANOVA compared to baseline (n = 8/group).Cmielewski et al. Respiratory Research 2010, 11:84
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Since the structural changes present in the molecular
variants of LPC are likely to alter their biological function
or effectiveness, we examined the effect of different
molecular variants of LPC on their ability to enhance LV
gene transfer. We used LPC variants based on their differ-
ing acyl chain length - from C10:0 decanoyl to C18:1
oleoyl- as well as at a low (0.1%) or a high (1%) concentra-
tion. Most biologically occurring LPC molecules possess
longer acyl chain lengths, between C16:0 and C22:6
[17,28].
The lack of effectiveness with decanoyl-C10:0 and
other shorter acyl chain LPC molecules mirrors the
known lack of effects on cell toxicity [29] and membrane
permeability [30] noted elsewhere. At the 0.1% concen-
tration LV gene expression was absent or not significantly
different to control (PBS) for the decanoyl-C10:0, lauroyl-
C12:0, myristoyl-C14:0 and oleoyl-C18:1 LPC pre-treat-
ment. In contrast, pre-treatment with palmitoyl-C16:0 or
stearoyl-C18:0 produced similar levels of gene transfer to
our standard LPC mixture (containing both C16:0 and
C18:0). Heptadecanoyl-C17:0 pre-treatment produced
the strongest LV gene expression of all those tested at the
0.1% concentration. These findings are consistent with
those in other studies where 0.1% LPC has produced suc-
cessful airway gene transfer in mice, rabbits and baboons
[8-10]. This present study also demonstrates that LPC
pretreatment can be effective at 1/10th of the dose previ-
ously used in mouse airway to enhance LV gene expres-
sion [12]. At the high concentration (1%) every LPC
variant except decanoyl-C10:0 produced similar levels of
LV gene transfer compared to our standard LPC mixture.
Figure 4 Correlation between LV gene transfer and 1 hr TPD depolarization. Change in low-chloride (see Methods) TPD at 60 min post LPC (solid 
bars) compared to LV gene transfer (grey bars) and corresponding correlation graph. a, c) 0.1% LPC and b, d) 1% LPC variants (n = 6-8/group).Cmielewski et al. Respiratory Research 2010, 11:84
http://respiratory-research.com/content/11/1/84
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The percentage of gene transduction ranged from 1.5%
(oleoyl-C18:1) to 15% (heptadecanoyl-C17:0) of the epi-
thelial respiratory cell layer, and if applicable to CFTR
gene transfer maybe sufficient for effective correction of
the CF gene defect in airways [31,32]. The majority of
respiratory cell types transduced at either concentration
were ciliated cells (60-72%), with the only other cell types
transduced being unciliated and basal cells. There was a
modest increase in the proportion of basal cells com-
pared to unciliated cells after 1% LPC pre-treatment. The
Figure 5 Mucin release after administration of LPC variants. Percentage of goblets cells remaining in nasal epithelium of treated vs untreated 
side, at 1 hr post a) 0.1% LPC and b) 1% LPC administration. *p < 0.05, ANOVA vs PBS (Holm-Sidak method, n = 8/group).
Figure 6 Nasal respiratory epithelia following LPC instillation. Examples of epithelial disturbance after LPC administration at the 60 min time 
point. Left side of tissue section is untreated and right side is treated. Goblet cells are those cells containing the compact darkly-stained contents (ex-
amples shown at dark arrows, untreated side). Scale bar = 50 μm. Low level effects, ranked at Level 1 (see Methods), displayed some loss of goblet cell 
mucins when compared to the untreated side (e.g. left panel). Disruption of the cell membrane junctions between cells, loss of some cilia and reduc-
tion in goblet mucin was ranked as Level 3 (e.g. middle panel, open arrow, treated side). An example of a region of complete exfoliation of epithelial 
layer produced by 1% LPC instillation is shown for comparison (Level 4, right panel).Cmielewski et al. Respiratory Research 2010, 11:84
http://respiratory-research.com/content/11/1/84
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increase in basal cell transduction could provide a basis
for effective long term LV expression, as this is the niche
where progenitor-like stem cells are thought to reside
[27].
We sought explanations for these differences in gene
transfer via electrophysiological and histological analyses.
The magnitude of depolarization of the electrical
response (TPD) one hour after 0.1% LPC administration
(the time of vector dosing) was strongly correlated with
h i g h e r  g e n e  t r a n s f e r ,  a s  m e a s u r e d  b y  c o u n t s  o f  c e l l s
expressing LacZ (Fig 4a, c). Since the TPD is reduced as
tight junction barrier function is lost [18] this finding
supports the idea that tight junctions become permeabi-
lised by LPC after treatment with most of the variants.
Such permeabilisation is known to permit viral vector
particles to access the relevant basolateral receptors [33],
with the ensuing increase in vector particle binding to
appropriate basolateral receptors resulting in increased
airway gene transfer. Conversely, when little or no depo-
larization was present 1 hour after the LPC treatment,
poor gene expression was observed (Fig. 4: see decanoyl-
C10:0 treatment group).
Another example of the influence of epithelial barrier
permeability was with 0.1% oleoyl-C18:1 LPC. Here the
change in potential difference was brief and transient,
with the TPD having returned to baseline by the usual
time of vector instillation, and the level of gene transfer
produced was low. This relationship between the TPD
and LPC pre-treatment suggests that improved gene
transduction may have been possible had the time of vec-
tor instillation corresponded to the maximum depolar-
ization of TPD (e.g. 30 min for this oleoyl LPC variant).
Optimization of successful gene transfer for a particular
LPC variant may depend on selecting the best pre-treat-
ment timing and LPC concentration for that variant, and
future studies could determine if the shorter timing inter-
vals are more effective for variants such as oleoyl. This
notion is further supported by our finding that at the high
1% LPC concentration only the decanoyl-C10:0 variant
remained unable to induce necessary membrane permea-
bility as measured electrophysiologically, and this was
consistent with the absence of gene transfer.
At the two concentrations tested, the LPC variants dis-
played differences in the degree of effect on the airway
epithelium morphology. We examined both the release of
cell-bound mucosubstances and changes to the physical
integrity of the epithelium. Mucosubstance changes were
particularly evident as a loss of mucin granules from epi-
thelial goblet cells; this is a normal airway response in
defense against foreign stimuli and particles and will aid
efficient mucus based particle capture and subsequent
mucociliary clearance. The lack of effect from control
vehicle administrations at the one hour time point (Fig. 5)
showed there was no significant release of mucin from
the epithelial cells from the delivery process of PBS, and
this was also observed after decanoyl-C10:0 administra-
Figure 7 Rank measurements of epithelial disruption after LPC variant administration. Epithelial disturbance due to a) 0.1% and b) 1% LPC ad-
ministration, at the 60 min time point. *p < 0.05, Wilcoxon Signed Rank vs PBS (n = 8/group).Cmielewski et al. Respiratory Research 2010, 11:84
http://respiratory-research.com/content/11/1/84
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tions. Consequently, the LV vector that is instilled at this
time will still encounter a primed mucociliary clearance
system (as well as intact tight-junctions), and this may
explain in part, the absence of any enhancement of gene
transfer by PBS or decanoyl-C10:0 LPC when used as a
pretreatment agent. The significant increase in the
release of mucin from the epithelial goblet cells in reac-
tion to the remaining LPC variants suggests an innate
mucin-based defense exists towards these molecules.
Thus, at the time of gene vector instillation most goblet
cells will have previously released their mucin. We specu-
late that the initial loss of mucins in response to LPC
delivery may be an additional factor in increasing gene
transfer and expression, by leaving the airway temporarily
unable to capture and remove the vector gene particles
when they are delivered 1 hour later.
All LPC pretreatments that produced effective gene
expression displayed physical perturbations of the epithe-
lial layer apparent 1 hour after LPC administration. These
included loss of cilia, disruption of cell-cell junctions and
even exfoliation of some areas (Fig. 7). Where cellular
exfoliation was induced in some regions (typically using
the 1% doses of LPC variants) we found that gene expres-
sion decreased (significantly for heptadecanoyl-C17:0
and stearoyl-C18:0 only) compared to that produced by
the low (0.1%) concentration of LPC. The high LPC con-
centration produced greater physical disruption than the
low LPC concentration, but the level of gene transfer was
similar in majority of cases. If the effect of the high dose
LPC is mainly to damage the epithelium, the potential for
production of gene expression maybe lost or reduced
because of cell re-growth [34]. That is, as much gene
expression may be lost, as would be regained, by creation
and transduction of newly formed epithelial cells. How-
ever, these physical disturbances to the epithelial layer
were in all cases (even at 1%) temporary, because the gene
expression noted at 1 week was within an intact epithelial
layer. Our data regarding the level of gene transfer
achieved, the effect on mucin release, changes in electro-
physiology, and epithelial disturbance supports our selec-
tion (and that of others [8,9]) to use a low dose (0.1%) of
LPC for pre-treatment or co-instillation in the produc-
tion of enhanced LV gene expression [12]. In addition, the
widely used C16:C18 mixture remains a good choice of
LPC variant. The use of LPC pretreatment also allows for
lower volumes and titres of a LV vector to achieve effec-
tive gene expression and therefore has the potential to
r e d u c e  i m m u n e  r e s p o n s e s .  H o w e v e r ,  h e p t a d e c a n o y l -
C17:0 used at the 0.1% concentration (Fig. 1b) can pro-
vide significant improvement in gene transfer effective-
ness over all other LPC variants tested here. For that
reason this LPC variant may be worthy of further investi-
gation, but some caution may be required for in vivo
application and/or clinical development as this molecule
is an entirely synthetic species not normally present in
biological systems.
In summary, optimization of the LPC species, the con-
centration, and the timing of the dose prior to vector
delivery can identify potentially valuable improvements
in gene expression efficiency in this in vivo gene transfer
enhancement setting. The potential advantage in a reduc-
tion of immune responses to the transgene of interest
may add to the benefits of the pre-treatment enhance-
ment itself. For successful gene therapy for diseases such
as cystic fibrosis, arranging significant improvements in
gene expression efficacy represents a valuable step in the
development of techniques suitable for use in airway gene
transfer clinical trials.
Conclusions
We have shown that LV gene transduction in murine air-
ways can be significantly enhanced by the optimization
and selection of LPC species as a pre-treatment regime.
The effect of LPC variants on airway barrier function
strongly correlated with gene transduction efficiency,
providing further development towards pre-clinical gene
therapy protocols.
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